Needham Reiterates Buy Rating on Biogen Inc. with $256 Target
Needham continues to see potential in Biogen Inc., maintaining its buy rating and a $256 price target, a 18.17% upside from the current price.
Key Points
- Needham reiterated its buy rating on Biogen Inc. (BIIB) with a price target of $256 as of June 29, 2026.
- Needham's $256 price target implies 18.17% upside from Biogen Inc.'s ($BIIB) current $216.63 share price.
- Shares of Biogen Inc. traded at $216.03 on Monday, with a market cap of about $31.89 billion and a P/E ratio of 23.25.
- Insider buying was reported on June 9, 2026, with several insiders acquiring shares, highlighting ongoing interest in the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 29, 2026, Needham reiterated its buy rating on Biogen Inc. (NasdaqGS: BIIB), setting a price target of $256. This reflects continued confidence in the company's potential, as evidenced by the maintained rating from analyst Ami Fadia.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Biogen Inc. Stock Down 0.9%
Shares of Biogen Inc. traded near $216.03 on Monday. The company, with a market cap of approximately $31.89 billion, has a P/E ratio of 23.25 and a forward P/E of 12.99. Biogen's beta is 0.177, indicating lower volatility compared to the market. The stock has a 52-week range between $121.05 and $218.06, with a 50-day moving average of $193.05 and a 200-day moving average of $176.24. Biogen maintains a healthy financial position with a current ratio of 3.07 and a quick ratio of 2.03, along with a debt-to-equity ratio of 35.18.
$BIIB price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Biogen reported revenue of approximately $9.94 billion, with a modest growth rate of 1.9%. The company achieved a net margin of 13.8% and a return on equity of 7.7%. Earnings per share stood at $9.29. The next earnings report is expected on July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
Several insiders showed activity on June 9, 2026. Menelas Pangalos bought 2,370 shares, while Eric Rowinsky, Stephen Sherwin, and Maria Freire also made purchases, each acquiring 1,505 shares. These transactions suggest ongoing interest from within the company, although Pangalos also sold an equal number of shares on the same day.
Analysts Set New Price Targets
On June 29, 2026, Needham maintained its buy rating on Biogen with a $256 price target. Previously, on June 18, Morgan Stanley maintained a hold rating with a $224 target. Mizuho, on June 15, also maintained a buy rating, setting a target of $221. The consensus among 31 analysts is a buy recommendation, with an average target price of $220.25.
About Biogen Inc.
Biogen Inc. is a healthcare company based in Cambridge, Massachusetts. It specializes in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is known for its treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Biogen collaborates with various partners to enhance its drug development pipeline and has a workforce of around 7,500 employees.
Bottom Line
Needham's reiteration of a buy rating for Biogen reflects continued confidence in the company's future prospects. While analyst ratings provide insights into market sentiment, investors should remember that these are based on past performance and expectations. As always, individual investment decisions should consider current market conditions and personal financial situations.
Get Biogen Inc. alerts
New 13F filings, insider trades, and analyst moves on $BIIB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.